Collegium PharmaceuticalCOLL +5.02%76 EV-to-FCF is 4.77 as of Jun. 28, 2026, which is 23% below its 10-year median of 6.21. GuruFocus rates COLL with a GF Score™ of 76/100 and a GF Value™ of $42.67 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 559 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 89.98% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Collegium Pharmaceutical's Enterprise Value is $1,573.1 Mil.
Collegium Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $329.8 Mil. Therefore, Collegium Pharmaceutical's EV-to-FCF for today is 4.77.
The historical rank and industry rank for Collegium Pharmaceutical's EV-to-FCF or its related term are showing as below:
COLL'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.5 Med: 6.21 Max: 33.27
Current: 4.77
During the past 13 years, the highest EV-to-FCF of Collegium Pharmaceutical was 33.27. The lowest was -22.50. And the median was 6.21.
COLL's EV-to-FCF is ranked better than 89.98% of 559
companies
in the Drug Manufacturers industry
Industry Median: 19.97
vs COLL: 4.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Collegium Pharmaceutical (NAS:COLL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Collegium Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Collegium Pharmaceutical's share price for today is $36.59.
Collegium Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Collegium Pharmaceutical EV-to-FCF Related Terms
Collegium Pharmaceutical EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's EV-to-FCF falls into.
Collegium Pharmaceutical's current Enterprise Value is $1,573.1 Mil.
Collegium Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $329.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (COLL) has a EV-to-FCF of 4.77 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Collegium Pharmaceutical and its competitors. This is 23% below median its historical median of 6.21. According to the industry distribution chart, Collegium Pharmaceutical ranks #56 out of 559 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Collegium Pharmaceutical's EV-to-FCF too high?
Collegium Pharmaceutical's current EV-to-FCF of 4.77 is 23% below median its 10-year median of 6.21. The Drug Manufacturers industry median EV-to-FCF is 19.97. Collegium Pharmaceutical's value of 4.77 is 76.1% below this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #56 out of 559 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Collegium Pharmaceutical has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's EV-to-FCF compare to XERS and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #56 out of 559 companies for EV-to-FCF. This places Collegium Pharmaceutical in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 19.97. Collegium Pharmaceutical's value of 4.77 is 76.1% below this benchmark. While the company's 10-year median is 6.21 vs. the industry median of 19.97, Collegium Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.97, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current EV-to-FCF of 4.77 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current EV-to-FCF is 4.77, which is 23% below median its own 10-year median of 6.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Modestly Undervalued. The stock's GF Value™ is $42.67, compared to a current price of $36.59 — trading 14.2% below its estimated fair value. The current EV-to-FCF is 4.77, which is 23% below median its 10-year median of 6.21 and 76.1% below the Drug Manufacturers industry median of 19.97. Collegium Pharmaceutical's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current EV-to-FCF is 4.77 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (COLL) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of $36.59 is trading 14.2% below its estimated GF Value™ of $42.67.
GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.
Key valuation signals for COLL:
EV-to-FCF: 4.77 (23% below median its 10-year median of 6.21)
GF Value™: $42.67 vs. price of $36.59 (14.2% below fair value)
Industry Position: 76.1% below the Drug Manufacturers median (#56 of 559)
No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
76GF Score
Get the complete analysis for COLL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COLL has been successfully added to your 
